The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.
Pakvisal N, Wongkongkathep P, Bunrasmee W, Sodsai P, Siriluksana J, Boonnak N, Sangcharoen T, Trakarnsanga B, Sukprakun S, Wantanasiri P, Chotirosniramit K, Phanichkrivalkosil M, Nanthawong S, Chanchaem P, Mankhong S, Kumpunya S, Supabphol S, Sirijun N, Kongtragulsub K, Pearngam P, Somparn P, Payne DM, Zhao B, Praphanphoj V, Pornputtapong N, Sriswasdi S, Wichadakul D, Uttamapinan S, Angspatt P, Wongchanapat P, Teeyapun N, Luangdilok S, Sitthideatphaiboon P, Susiriwatananont T, Zungsontiporn N, Parinyanitikul N, Tanasanvimon S, Vinayanuwattikun C, Salazar A, Hirankarn N, Sriuranpong V, Pisitkun T.
Pakvisal N, et al.
Clin Cancer Res. 2026 May 7. doi: 10.1158/1078-0432.CCR-25-4271. Online ahead of print.
Clin Cancer Res. 2026.
PMID: 42095629